ArticleCell death & disease2017
Oridonin induces autophagy via inhibition of glucose metabolism in p53-mutated colorectal cancer cells.
Article in Cell death & disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 116 citations in OpenAlex.
- Article
- Oridonin Suppresses Colorectal Cancer Growth In Vitro and In Vivo: Evidence from Integrated Transcriptomic and Proteomic Profiling.Current issues in molecular biology · 2026Article
- Divergent activation patterns of BRS3 revealed by two Chinese herb-derived agonists.Acta pharmaceutica Sinica. B · 2025Article
- Plant-derived terpenoids modulating cancer cell metabolism and cross-linked signaling pathways: an updated reviews.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- A Potential Role for Oridonin in Cancer Control: Mechanisms of Autophagy and Apoptosis.Current cancer drug targets · 2025Review
- Natural Products and Derivatives Targeting Metabolic Reprogramming in Colorectal Cancer: A Comprehensive Review.Metabolites · 2024Review
- Dual inhibitory potential of ganoderic acid A on GLUT1/3: computational andRSC advances · 2024Article
- Oridonin fromFood science & nutrition · 2024Review
- ThermomiR-377-3p-induced suppression of Cirbp expression is required for effective elimination of cancer cells and cancer stem-like cells by hyperthermia.Journal of experimental & clinical cancer research : CR · 2024Article
- Terpenoid-Mediated Targeting of STAT3 Signaling in Cancer: An Overview of Preclinical Studies.Biomolecules · 2024Review
- Enhancing cancer therapy: advanced nanovehicle delivery systems for oridonin.Frontiers in pharmacology · 2024Review
- The Natural Product Oridonin as an Anticancer Agent: Current Achievements and Problems.Current pharmaceutical biotechnology · 2024Review
- Oridonin restores hepatic lipid homeostasis in an LXRα-ATGL/EPT1 axis-dependent manner.Journal of pharmaceutical analysis · 2023Article
- Phytochemicals targeting glycolysis in colorectal cancer therapy: effects and mechanisms of action.Frontiers in pharmacology · 2023Review
- Recent advances in oridonin derivatives with anticancer activity.Frontiers in chemistry · 2023Review
- New Visions on Natural Products and Cancer Therapy: Autophagy and Related Regulatory Pathways.Cancers · 2022Review
- Role of AMPK in Regulation of Oxaliplatin-Resistant Human Colorectal Cancer.Biomedicines · 2022Article
- Traditional Medicinal Plants as a Source of Inspiration for Osteosarcoma Therapy.Molecules (Basel, Switzerland) · 2022Review
- Role of Plant-Derived Active Constituents in Cancer Treatment and Their Mechanisms of Action.Cells · 2022Review
- Oridonin enhances antitumor effects of doxorubicin in human osteosarcoma cells.Pharmacological reports : PR · 2022Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Warburg effect is an important characteristic of tumor cells, making it an attractive therapeutic target. Current anticancer drug development strategies predominantly focus on inhibitors of the specific molecular effectors involved in tumor cell proliferation. These drugs or natural compounds, many of which target the Warburg effect and the underlying mechanisms, still need to be characterized. To elucidate the anticancer effects of a natural diterpenoid, oridonin, we first demonstrated the anticancer activity of oridonin both in vitro and in vivo in colorectal cancer (CRC) cells. Then miRNA profiling of SW480 cells revealed those intracellular signaling related to energy supply was affected by oridonin, suggesting that glucose metabolism is a potential target for CRC therapy. Moreover, our results indicated that oridonin induced metabolic imbalances by significantly inhibiting glucose uptake and reducing lactate export through significantly downregulating the protein levels of GLUT1 and MCT1 in vitro and vivo. However, the ATP level in oridonin-treated CRC cells was not decreased when oridonin blocked the glucose supply, indicating that oridonin induced autophagy process, an important ATP source in cancer cells. The observation was then supported by the results of LC3-II detection and transmission electron microscopy analysis, which confirmed the presence of autophagy. Furthermore, p-AMPK was rapidly deactivated following oridonin treatment, resulting in downregulation of GLUT1 and induction of autophagy in the cancer cells. Thus our finding helped to clarify the anticancer mechanisms of oridonin and suggested it could be applied as a glucose metabolism-targeting agent for cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.